SOPHiA Genetics SA Profit Margin

The latest profit margin for SOPH is -99.7% as of March 2026. That compares with -98.51% in the prior-year period — down 1.2% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside SOPHiA Genetics SA's historical trend and sector peers before judging valuation or financial health.

Over the past year, SOPH's profit margin moved from -98.51% to -99.7% — a 1.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SOPHiA Genetics SA's valuation or profitability profile.

Against Healthcare companies, SOPH currently prints -99.7% for profit margin, while the sector average sits near 14.34%. That is roughly 795.0% below the sector mean. Large gaps often invite a closer look at SOPHiA Genetics SA's growth, margins, and balance sheet.

Profit Margin shows how effectively SOPHiA Genetics SA converts resources into returns. At -99.7%, SOPH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -98.51% in the prior-year period — down 1.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SOPH's profit margin (-99.7%), review year-over-year change from -98.51%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.